1 Reason to Sell Novavax Stock, and 1 Reason to Buy
This year hasn't been an easy one for Novavax (NASDAQ: NVAX) investors. After a series of stumbles culminating in its disastrous earnings report on Aug. 8, its shares are down by 60% so far in 2022. And with management slashing its full-year revenue guidance by roughly half, there isn't much hope for smoother sailing for at least a few quarters.
For a contrarian investor, that means the stock could be ripe for a buy with the goal of holding it through a turnaround. On the other hand, most of us aren't contrarians, so now could be the time to cut and run, or at least defer a purchase until conditions improve.
On that note, here's one argument for selling your shares and one for buying more.
Source Fool.com
